Cell Carcinoma clinical trials

Explore recruiting cell carcinoma clinical trials.

Recruiting cell carcinoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cell Carcinoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2/3, Randomized, Double-Blind, Controlled Study of XL092 in Combination With Pembrolizumab vs Pembrolizumab in the First-Line Treatment of Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Slovakia, France, Romania, Greece, Poland, Bulgaria +7 more

Phase II and Phase III (Integrated) EU CTIS Study details

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants from Multiple Avelumab (MSB0010718C) Clinical Studies

Italy, Bulgaria, Poland, Romania, France, Spain +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Digital monitoring of self-reported symptoms by patients treated with Cabozantinib plus Nivolumab for advanced clear-cell renal carcinoma: The CANIQOL multicentre study

France

Therapeutic use (Phase IV) EU CTIS Study details

AFAN trial. Phase Ib/II study to investigate the safety and efficacy of Afatinib when administered as therapy in Fanconi anemia patients with unresectable and / or metastatic locoregionally advanced squamous cell carcinoma of the oral cavity, oropharynx or hypopharynx or larynx

Spain, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

BelieveIT-201: A Randomized, Phase 2, Open-label Trial of TransCon TLR7/8 Agonist in Combination with Pembrolizumab, TransCon TLR7/8 Agonist in Combination with TransCon IL-2 β/γ, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)

Spain, Hungary, Poland, Germany, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

IFCT-2103 DIAL De-escalation Immunotherapy mAintenance duration trial for stage IV Lung cancer patients with disease control after chemo-immunotherapy induction A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) after 6 months of platinum-based doublet chemotherapy plus pembrolizumab induction treatment in patients with stage IV Non-Small Cell Lung Cancer (NSCLC)

France

Phase II and Phase III (Integrated) EU CTIS Study details

Cell Carcinoma trials by city

Cell Carcinoma in Toronto Cell Carcinoma in Vancouver Cell Carcinoma in Montreal Cell Carcinoma in Calgary Cell Carcinoma in Edmonton Cell Carcinoma in Ottawa Cell Carcinoma in Winnipeg Cell Carcinoma in Quebec City Cell Carcinoma in Hamilton Cell Carcinoma in Kitchener Cell Carcinoma in London Cell Carcinoma in Halifax Cell Carcinoma in New York Cell Carcinoma in Los Angeles Cell Carcinoma in Chicago Cell Carcinoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease